Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT
Abstract
:1. Introduction
2. Material and Methods
2.1. Patient Population
2.2. Radiopharmaceutical
2.3. Imaging Protocol
2.4. Image Analysis
2.5. Statistical Analysis
3. Results
3.1. PET/CT Studies 60 min p.i.
3.2. Early PET/CT Studies
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021. [Google Scholar] [CrossRef] [PubMed]
- Schwarzenboeck, S.M.; Rauscher, I.; Bluemel, C.; Fendler, W.P.; Rowe, S.P.; Pomper, M.G.; Afshar-Oromieh, A.; Herrmann, K.; Eiber, M. PSMA Ligands for PET Imaging of Prostate Cancer. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2017, 58, 1545–1552. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beheshti, M.; Manafi-Farid, R.; Geinitz, H.; Vali, R.; Loidl, W.; Mottaghy, F.M.; Langsteger, W. Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2020, 61, 1484–1490. [Google Scholar] [CrossRef]
- Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G.; Hadaschik, B.A.; Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Haufe, S.; et al. PET imaging with a 68Gagallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 486–495. [Google Scholar] [CrossRef] [PubMed]
- Fendler, W.P.; Calais, J.; Eiber, M.; Flavell, R.R.; Mishoe, A.; Feng, F.Y.; Nguyen, H.G.; Reiter, R.E.; Rettig, M.B.; Okamoto, S.; et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019, 5, 856–863. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Freitag, M.T.; Radtke, J.P.; Afshar-Oromieh, A.; Roethke, M.C.; Hadaschik, B.A.; Gleave, M.; Bonekamp, D.; Kopka, K.; Eder, M.; Heusser, T.; et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: Comparison with mpMRI integrated in simultaneous PET/MRI. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 776–787. [Google Scholar] [CrossRef]
- Uprimny, C.; Bayerschmidt, S.; Kroiss, A.S.; Fritz, J.; Nilica, B.; Svirydenka, A.; Decristoforo, C.; Di Santo, G.; von Guggenberg, E.; Horninger, W.; et al. Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on 68GaGa-PSMA-11-PET/CT in the evaluation of prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 123–133. [Google Scholar] [CrossRef]
- Fendler, W.P.; Eiber, M.; Beheshti, M.; Bomanji, J.; Ceci, F.; Cho, S.; Giesel, F.; Haberkorn, U.; Hope, T.A.; Kopka, K.; et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: Version 1.0. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 1014–1024. [Google Scholar] [CrossRef]
- Uprimny, C.; Bayerschmidt, S.; Kroiss, A.S.; Fritz, J.; Nilica, B.; Svirydenka, H.; Decristoforo, C.; von Guggenberg, E.; Horninger, W.; Virgolini, I.J. Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET/CT. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2021. [Google Scholar] [CrossRef]
- Uprimny, C.; Kroiss, A.S.; Decristoforo, C.; Fritz, J.; Warwitz, B.; Scarpa, L.; Roig, L.G.; Kendler, D.; von Guggenberg, E.; Bektic, J.; et al. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 765–775. [Google Scholar] [CrossRef]
- Uprimny, C.; Kroiss, A.S.; Fritz, J.; Decristoforo, C.; Kendler, D.; von Guggenberg, E.; Nilica, B.; Maffey-Steffan, J.; Di Santo, G.; Bektic, J.; et al. Early PET imaging with 68Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 1647–1655. [Google Scholar] [CrossRef] [PubMed]
- World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2000, 284, 3043–3045. [CrossRef]
- Uprimny, C. 68Ga-PSMA-11 PET/CT: The rising star of nuclear medicine in prostate cancer imaging? Wien. Med. Wochenschr. 2019, 169, 3–11. [Google Scholar] [CrossRef]
- Fanti, S.; Minozzi, S.; Morigi, J.J.; Giesel, F.; Ceci, F.; Uprimny, C.; Hofman, M.S.; Eiber, M.; Schwarzenbock, S.; Castellucci, P.; et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 1622–1635. [Google Scholar] [CrossRef] [PubMed]
- Eiber, M.; Herrmann, K.; Calais, J.; Hadaschik, B.; Giesel, F.L.; Hartenbach, M.; Hope, T.; Reiter, R.; Maurer, T.; Weber, W.A.; et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2018, 59, 469–478. [Google Scholar] [CrossRef] [Green Version]
- Ceci, F.; Oprea-Lager, D.E.; Emmett, L.; Adam, J.A.; Bomanji, J.; Czernin, J.; Eiber, M.; Haberkorn, U.; Hofman, M.S.; Hope, T.A.; et al. E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1626–1638. [Google Scholar] [CrossRef]
- Afshar-Oromieh, A.; Sattler, L.P.; Mier, W.; Hadaschik, B.A.; Debus, J.; Holland-Letz, T.; Kopka, K.; Haberkorn, U. The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2017, 58, 750–755. [Google Scholar] [CrossRef] [Green Version]
- Haupt, F.; Dijkstra, L.; Alberts, I.; Sachpekidis, C.; Fech, V.; Boxler, S.; Gross, T.; Holland-Letz, T.; Zacho, H.D.; Haberkorn, U.; et al. 68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 624–631. [Google Scholar] [CrossRef] [PubMed]
- Chevalme, Y.-M.; Boudali, L.; Gauthé, M.; Rousseau, C.; Skanjeti, A.; Merlin, C.; Robin, P.; Giraudet, A.-L.; Janier, M.; Talbot, J.-N. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations. Eur. J. Nucl. Med. Mol. Imaging 2021. [Google Scholar] [CrossRef]
- Alberts, I.; Huenermund, J.N.; Sachpekidis, C.; Zacho, H.D.; Mingels, C.; Dijkstra, L.; Bohn, K.P.; Laeppchen, T.; Gourni, E.; Rominger, A.; et al. Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET/CT—Effects on lesion visibility and radiotracer uptake. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2021. [Google Scholar] [CrossRef]
- Kabasakal, L.; Demirci, E.; Ocak, M.; Akyel, R.; Nematyazar, J.; Aygun, A.; Halac, M.; Talat, Z.; Araman, A. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl. Med. Commun. 2015, 36, 582–587. [Google Scholar] [CrossRef] [PubMed]
- Mitran, B.; Varasteh, Z.; Abouzayed, A.; Rinne, S.S.; Puuvuori, E.; de Rosa, M.; Larhed, M.; Tolmachev, V.; Orlova, A.; Rosenström, U. Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. Cancers 2019, 11, 1371. [Google Scholar] [CrossRef] [Green Version]
- Perveen, G.; Arora, G.; Damle, N.A.; Prabhu, M.; Arora, S.; Tripathi, M.; Bal, C.; Kumar, P.; Kumar, R.; Singh, P.; et al. Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in 68Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma? Indian J. Nucl. Med. IJNM Off. J. Soc. Nucl. Med. India 2018, 33, 202–208. [Google Scholar] [CrossRef]
- Fennessy, N.; Lee, J.; Shin, J.; Ho, B.; Ali, S.A.; Paschkewitz, R.; Emmett, L. Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer. J. Med. Imaging Radiat. Oncol. 2017, 61, 739–744. [Google Scholar] [CrossRef]
- Uprimny, C.; Kroiss, A.S.; Decristoforo, C.; Fritz, J.; von Guggenberg, E.; Kendler, D.; Scarpa, L.; Di Santo, G.; Roig, L.G.; Maffey-Steffan, J.; et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 941–949. [Google Scholar] [CrossRef]
- Ponto, L.L.; Schoenwald, R.D. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin. Pharmacokinet. 1990, 18, 381–408. [Google Scholar] [CrossRef] [PubMed]
Patients | 190 |
Primary radical prostatectomy | 166 |
Primary radiation therapy | 24 |
Salvage radiotherapy | 58 |
Androgen deprivation therapy | 41 |
Initial Gleason score, median (range) | 7 (5–10) * |
PSA (ng/mL), median (range) | 0.7 (0.1–105.6) |
Age (years), median (range) | 71 (44–87) |
Body mass index | 26.1 (18.6–36.6) |
Early | 60 min p.i. | p-Value * | |
---|---|---|---|
Negative | 143 (75.3%) | 137 (72.1%) | 0.327 |
Positive | 30 (15.8%) | 28 (14.7%) | 0.815 |
Equivocal | 17 (8.9%) | 25 (13.2%) | 0.152 |
SUVmax lesion | 4.9 (2.0–55.2) | 8.0 (2.1–139.9) | |
SUVmax bladder | 2.5 (0.9–12.2) | 8.2 (1.8–48.7) |
60 min p.i. | Combination | p-Value * | |
---|---|---|---|
Negative | 137 (72.1%) | 137 (72.1%) | 1 |
Positive | 28 (14.7%) | 33 (17.4%) | 0.063 |
Equivocal | 25 (13.2%) | 20 (10.5%) | 0.063 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bayerschmidt, S.; Uprimny, C.; Kroiss, A.S.; Fritz, J.; Nilica, B.; Svirydenka, H.; Decristoforo, C.; von Guggenberg, E.; Horninger, W.; Virgolini, I.J. Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT. Diagnostics 2021, 11, 1191. https://doi.org/10.3390/diagnostics11071191
Bayerschmidt S, Uprimny C, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ. Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT. Diagnostics. 2021; 11(7):1191. https://doi.org/10.3390/diagnostics11071191
Chicago/Turabian StyleBayerschmidt, Steffen, Christian Uprimny, Alexander Stephan Kroiss, Josef Fritz, Bernhard Nilica, Hanna Svirydenka, Clemens Decristoforo, Elisabeth von Guggenberg, Wolfgang Horninger, and Irene Johanna Virgolini. 2021. "Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT" Diagnostics 11, no. 7: 1191. https://doi.org/10.3390/diagnostics11071191